Progress in human tumour immunology and immunotherapy
暂无分享,去创建一个
[1] R. Henderson,et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. , 1994, Science.
[2] C. Figdor,et al. The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes. , 1999, Cancer research.
[3] J. Shabanowitz,et al. Biochemical Identification of a Mutated Human Melanoma Antigen Recognized by CD4+ T Cells , 1999, The Journal of experimental medicine.
[4] A. Sette,et al. Synthetic peptides derived from the melanocyte-stimulating hormone receptor MC1R can stimulate HLA-A2-restricted cytotoxic T lymphocytes that recognize naturally processed peptides on human melanoma cells. , 1997, Cancer research.
[5] S. Rosenberg,et al. Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[6] S. Rosenberg,et al. T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes. , 2000, Cancer journal.
[7] S. Hoffman,et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. , 1998, Science.
[8] P. Coulie,et al. Tumor antigens recognized by T cells. , 1997, Immunology today.
[9] J. Patard,et al. An antigen recognized by autologous CTLs on a human bladder carcinoma. , 1998, Journal of immunology.
[10] F. Marincola,et al. A Tumor-Infiltrating Lymphocyte from a Melanoma Metastasis with Decreased Expression of Melanoma Differentiation Antigens Recognizes MAGE-12 , 2000, The Journal of Immunology.
[11] W. M. Linehan,et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. , 1987, The New England journal of medicine.
[12] A. Chang,et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. , 1985, The New England journal of medicine.
[13] O. de Backer,et al. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma , 1995, The Journal of experimental medicine.
[14] S. Rosenberg,et al. Identification of a Novel Major Histocompatibility Complex Class II–restricted Tumor Antigen Resulting from a Chromosomal Rearrangement Recognized by CD4+ T Cells , 1999, The Journal of experimental medicine.
[15] A. Sette,et al. The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. , 1998, Human immunology.
[16] A. Eggermont,et al. Identification of MAGE-3 Epitopes Presented by HLA-DR Molecules to CD4+ T Lymphocytes , 1999, The Journal of experimental medicine.
[17] N. Restifo,et al. The promise of nucleic acid vaccines , 2000, Gene Therapy.
[18] P. Chomez,et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.
[19] R. Bast,et al. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. , 1991, Cancer research.
[20] Yao-Tseng Chen,et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[21] A. Ribas,et al. Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein. , 1999, Cancer research.
[22] S. H. van der Burg,et al. Identification of HLA‐A*0201‐restricted CTL epitopes encoded by the tumor‐specific MAGE‐2 gene product , 1997, International journal of cancer.
[23] A. Levine,et al. Targeting p53 as a general tumor antigen. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[24] P. Coulie,et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas , 1993, The Journal of experimental medicine.
[25] R. Fisher,et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] S. Rosenberg,et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. , 1988, The New England journal of medicine.
[27] F. Marincola,et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. , 1998, Journal of the National Cancer Institute.
[28] J. Marshall,et al. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] S. Rosenberg,et al. Principles and Practice of the Biologic Therapy of Cancer , 2000 .
[30] S. Cannistra,et al. Fusions of Human Ovarian Carcinoma Cells with Autologous or Allogeneic Dendritic Cells Induce Antitumor Immunity1 , 2000, The Journal of Immunology.
[31] V. Devita,et al. Cancer : Principles and Practice of Oncology , 1982 .
[32] F. Marincola,et al. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. , 1999, Journal of immunology.
[33] S. Rosenberg,et al. Gene therapy for cancer. , 1992, JAMA.
[34] S. Rosenberg,et al. Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. , 1999, Science.
[35] S. Rosenberg,et al. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes [published erratum appears in J Exp Med 1995 Mar 1;181(3):1261] , 1995, The Journal of experimental medicine.
[36] K. Landsteiner,et al. Experiments on Transfer of Cutaneous Sensitivity to Simple Compounds , 1942 .
[37] R. Henderson,et al. Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. , 1992, Science.
[38] E. Gehan,et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] A Sette,et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. , 1996, Journal of immunology.
[40] C. Balch,et al. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor , 1988, The Journal of experimental medicine.
[41] H. Hewitt,et al. A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. , 1976, British Journal of Cancer.
[42] W. Hahn,et al. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. , 1999, Immunity.
[43] E. Klein,et al. Humoral and cellular factors in homograft and isograft immunity against sarcoma cells. , 1960, Cancer research.
[44] N. Petrelli,et al. The onset and extent of genomic instability in sporadic colorectal tumor progression. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[45] E. Appella,et al. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes , 1996, The Journal of experimental medicine.
[46] Thomas Halder,et al. Tumour-specific MHC-class-II-restricted responses after in vitro sensitization to synthetic peptides corresponding to gp100 and Annexin II eluted from melanoma cells , 1998, Cancer Immunology, Immunotherapy.
[47] S. Rosenberg,et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. , 1994, Journal of the National Cancer Institute.
[48] L. Old,et al. ANTIGENIC PROPERTIES OF CHEMICALLY INDUCED TUMORS * , 1962 .
[49] S. Rosenberg,et al. A new era for cancer immunotherapy based on the genes that encode cancer antigens. , 1999, Immunity.
[50] F. Brasseur,et al. A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma , 1996, The Journal of experimental medicine.
[51] J. Wharton,et al. Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene. , 1993, Cellular immunology.
[52] S. Steinberg,et al. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. , 1998, Annals of surgery.
[53] S. Riddell,et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. , 1995, The New England journal of medicine.
[54] K. Sakaguchi,et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[55] S. Rosenberg,et al. Identification of CD4+ T Cell Epitopes from NY-ESO-1 Presented by HLA-DR Molecules , 2000, The Journal of Immunology.
[56] R. Fisher,et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] S. Rosenberg,et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[58] M. Serrano,et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma , 1995, Science.
[59] M. Ladanyi,et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. , 1994, The New England journal of medicine.
[60] R. Brasseur,et al. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. , 1995, Immunity.
[61] F. Foury,et al. Two antigens recognized by autologous cytolytic T lymphocytes on a melanoma result from a single point mutation in an essential housekeeping gene. , 1999, Cancer research.
[62] P. Kantoff,et al. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[63] S. Rosenberg,et al. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. , 1987, Journal of immunology.
[64] P. Romero,et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes , 1994, The Journal of experimental medicine.
[65] F. Marincola,et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma , 1998, Nature Medicine.
[66] S. Rosenberg,et al. A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. , 1998, Journal of immunology.
[67] J. Schlom,et al. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. , 1995, Journal of the National Cancer Institute.
[68] F. Brasseur,et al. A CASP-8 Mutation Recognized by Cytolytic T Lymphocytes on a Human Head and Neck Carcinoma , 1997, The Journal of experimental medicine.
[69] J. Thompson,et al. Isolation of tyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus. , 1996, Journal of immunology.